Gufic BioSciences Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter.

Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review.

EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24.

Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.

Powered by Capital Market - Live News

Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter.

Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review.

EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24.

Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.

The scrip rose 1.95% o settle at Rs 446.65 on Thursday, 14 November 2024, the domestic stock market to remain closed today on account of Guru Nanak Jayanti.

Powered by Capital Market - Live News

Net profit of Gufic BioSciences declined 6.16% to Rs 21.78 crore in the quarter ended September 2024 as against Rs 23.21 crore during the previous quarter ended September 2023. Sales declined 4.98% to Rs 204.18 crore in the quarter ended September 2024 as against Rs 214.87 crore during the previous quarter ended September 2023.

Powered by Capital Market - Live News

Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 14 November 2024

Powered by Capital Market - Live News